CLOs on the Move

Neoleukin

www.neoleukin.com

 
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.neoleukin.com
  • 188 East Blaine Suite 450
    Seattle, WA USA 98102
  • Phone: 855.226.6447

Executives

Name Title Contact Details
Holly Vance
General Counsel Profile
Donna Cochener
General Counsel Profile
Donna Cochener
Interim Chief Executive Officer, Senior Vice President of Legal and General Counsel Profile
Leslie Aberman
Vice President of Legal Affairs and Intellectual Property Profile

Similar Companies

Myriant Technologies

At Myriant, we know there`s a better, greener way to produce the products people use every day. And we`re realizing that vision—displacing barrels of petroleum by manufacturing and selling high-value chemicals made from renewable, sustainable feedstocks. As companies and consumers look for ways to reduce their carbon footprint and transition away from petroleum`s price volatility, Myriant has the solution: our proven technology platform and strategic feedstock selection enable Myriant to deliver high-quality, high-performing, green chemicals at a competitive, more-predictable cost versus petroleum-based chemicals without the need for government subsidies. That`s what we call a sustainable advantage.

Affinia Therapeutics

We are working to methodically engineer durable gene therapies for people with devastating diseases.

Angstrom Scientific

Angstrom Scientific is a Ramsey, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nova Biologics.

Nova Biologics. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Istari Oncology

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.